{
    "data": [
        {
            "id": "69a0c2af24c37e0001bbc598",
            "title": "NovoCure Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">4 analysts have expressed a variety of opinions on NovoCure (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/NVCR\" target=\"_blank\">NVCR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p><!--/$--><!--$--><p class=\"block core-block\">The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><!--/$--><!--$--><p class=\"block core-block\">In the assessment of 12-month price targets, analysts unveil insights for NovoCure, presenting an average target of $38.25, a high estimate of $49.00, and a low estimate of $18.00. This current average reflects an increase of 4.79% from the previous average price target of $36.50. </p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><h2 class=\"block core-block\">Analyzing Analyst Ratings: A Detailed Breakdown</h2><!--/$--><!--$--><p class=\"block core-block\">The standing of NovoCure among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p><!--/$--><!--$?--><template id=\"B:3\"></template><div></div><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h3 class=\"block core-block\">Key Insights:</h3><!--/$--><!--$?--><template id=\"B:4\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of NovoCure's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p><!--/$--><!--$--><p class=\"block core-block\"><a href=\"https://www.benzinga.com/quote/NVCR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage\" target=\"_blank\"><strong>Stay up to date on NovoCure analyst ratings.</strong></a></p><!--/$--><!--$--><p class=\"block core-block\">If you are interested in following small-cap stock news and performance <a href=\"https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage\" target=\"_blank\">you can start by tracking it here</a>.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"block core-block\">All You Need to Know About NovoCure</h2><!--/$--><!--$?--><template id=\"B:5\"></template><div></div><!--/$--><!--$--><h3 class=\"block core-block\">Financial Insights: NovoCure</h3><!--/$--><!--$--><p class=\"block core-block\"><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>Revenue Growth:</strong> NovoCure's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of <strong>7.81%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Net Margin:</strong> NovoCure's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-22.29%,</strong> the company may encounter challenges in effective cost control.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Return on Equity (ROE):</strong> NovoCure's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-10.79%,</strong> the company may face hurdles in achieving optimal financial performance.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Return on Assets (ROA):</strong> NovoCure's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-2.86%,</strong> the company may face hurdles in generating optimal returns from its assets.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Debt Management:</strong> NovoCure's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>2.34</strong>.</p><!--/$--><!--$--><h2 class=\"block core-block\">What Are Analyst Ratings?</h2><!--/$--><!--$--><p class=\"block core-block\">Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p><!--/$--><!--$--><p class=\"block core-block\">Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p><!--/$--><!--$--><p class=\"block core-block\">This article was generated by Benzinga's automated content engine and reviewed by an editor.</p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/11/06/analyst_ratings_8.jpg",
            "link": "https://www.benzinga.com/insights/analyst-ratings/26/02/50914966/novocure-stock-a-deep-dive-into-analyst-perspectives-4-ratings",
            "pub_date": "2026-02-27 06:01:22",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a0c2b724c37e0001bbc5ae",
            "title": "Acadia Healthcare Co Stock: A Deep Dive Into Analyst Perspectives (17 Ratings)",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">Ratings for Acadia Healthcare Co (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/ACHC\" target=\"_blank\">ACHC</a>) were provided by 17 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p><!--/$--><!--$--><p class=\"block core-block\">The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><!--/$--><!--$--><p class=\"block core-block\">The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $20.0, a high estimate of $28.00, and a low estimate of $13.00. A 15.54% drop is evident in the current average compared to the previous average price target of $23.68. </p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><h2 class=\"block core-block\">Deciphering Analyst Ratings: An In-Depth Analysis</h2><!--/$--><!--$--><p class=\"block core-block\">An in-depth analysis of recent analyst actions unveils how financial experts perceive Acadia Healthcare Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p><!--/$--><!--$?--><template id=\"B:3\"></template><div></div><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h3 class=\"block core-block\">Key Insights:</h3><!--/$--><!--$?--><template id=\"B:4\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Acadia Healthcare Co's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p><!--/$--><!--$--><p class=\"block core-block\"><a href=\"https://www.benzinga.com/quote/ACHC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage\" target=\"_blank\"><strong>Stay up to date on Acadia Healthcare Co analyst ratings.</strong></a></p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"block core-block\">Delving into Acadia Healthcare Co's Background</h2><!--/$--><!--$--><p class=\"block core-block\">Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.</p><!--/$--><!--$--><h3 class=\"block core-block\">Acadia Healthcare Co: Delving into Financials</h3><!--/$--><!--$--><p class=\"block core-block\"><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>Revenue Growth:</strong> Over the 3M period, Acadia Healthcare Co showcased positive performance, achieving a revenue growth rate of <strong>4.41%</strong> as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Net Margin:</strong> Acadia Healthcare Co's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>4.26%,</strong> the company showcases strong profitability and effective cost management.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>1.17%,</strong> the company showcases effective utilization of equity capital.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Return on Assets (ROA):</strong> Acadia Healthcare Co's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.57%,</strong> the company may face hurdles in achieving optimal financial performance.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Debt Management:</strong> Acadia Healthcare Co's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.78</strong>.</p><!--/$--><!--$--><h2 class=\"block core-block\">The Core of Analyst Ratings: What Every Investor Should Know</h2><!--/$--><!--$--><p class=\"block core-block\">Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p><!--/$--><!--$--><p class=\"block core-block\">Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p><!--/$--><!--$--><p class=\"block core-block\">This article was generated by Benzinga's automated content engine and reviewed by an editor.</p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/11/06/analyst_ratings_7.jpg",
            "link": "https://www.benzinga.com/insights/analyst-ratings/26/02/50914984/acadia-healthcare-co-stock-a-deep-dive-into-analyst-perspectives-17-ratings",
            "pub_date": "2026-02-27 06:01:31",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a0c05124c37e0001bbc1aa",
            "title": "MP Materials Stock Slips On Mixed Q4 Results",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>MP Materials Corp</strong> <a class=\"ticker-link\" data-exchange=\"NYSE\" data-ticker=\"MP\" href=\"https://www.benzinga.com/quote/MP\" rel=\"noopener\" target=\"_blank\">(NYSE:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/MP\" target=\"_blank\">MP</a>)<!-- --> reported fourth-quarter financial results Thursday after the close. Here are the key highlights <a href=\"https://www.benzinga.com/pressreleases/26/02/b50909033/mp-materials-reports-fourth-quarter-and-full-year-2025-results\" target=\"_blank\">from the quarter</a>. </p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>MP Materials stock is trending. <a href=\"https://www.benzinga.com/quote/MP\" rel=\"noreferrer noopener\" target=\"_blank\">What’s driving MP shares?</a></strong></li>\n</ul><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\"><strong>MP Delivers Mixed Quarterly Results</strong></h2><!--/$--><!--$--><p class=\"block core-block\">MP Materials reported fourth-quarter revenue of $52.69 million, missing analyst <a href=\"http://benzinga.com/quote/mp/earnings\" rel=\"noreferrer noopener\" target=\"_blank\">estimates</a> of $67.38 million, according to <a href=\"http://pro.benzinga.com/\" rel=\"noreferrer noopener\" target=\"_blank\">Benzinga Pro</a>. The company reported fourth-quarter adjusted earnings of nine cents per share, beating analyst estimates for breakeven earnings.</p><!--/$--><!--$--><p class=\"block core-block\">Total revenue was down 14% on a year-over-year basis after the company ceased all sales of its products to China in support of its domestic supply chain objectives.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><p class=\"block core-block\">MP said it produced 718 metric tons of NdPr oxide in the quarter, up 74% year-over-year, and 50,692 metric tons of rare earth concentrate, up 12% year-over-year. </p><!--/$--><!--$--><p class=\"block core-block\">“Our landmark partnership with the U.S. Department of War, together with our agreement with Apple to deliver scaled recycling and magnetics capabilities, anchors a durable platform to accelerate growth and extend our vertically integrated advantage,” said <strong>James Litinsky</strong>, founder, chairman and CEO of MP Materials.</p><!--/$--><!--$--><p class=\"block core-block\">MP Materials ended the quarter with $1.83 billion in cash, cash equivalents and short-term investments.</p><!--/$--><!--$--><p class=\"block core-block\">MP Materials executives will further discuss the quarter on an earnings call scheduled for 5 p.m. ET.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\"><strong>MP Stock Moves Lower After The Bell</strong></h2><!--/$--><!--$--><p class=\"block core-block\"><strong>MP Price Action:</strong> <a href=\"http://benzinga.com/quote/MP\" rel=\"noreferrer noopener\" target=\"_blank\">MP Materials shares</a> were down 2.83% in after-hours on Thursday, trading at $58.30 at the time of publication, according to <a href=\"http://pro.benzinga.com/\" rel=\"noreferrer noopener\" target=\"_blank\">Benzinga Pro</a>.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Photo: courtesy of MP Materials.</em></p><!--/$--><!--$--><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50914157\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/26/Screenshot-2025-04-21-at-2-30-46PM.png",
            "link": "https://www.benzinga.com/markets/earnings/26/02/50914157/mp-materials-stock-slips-on-mixed-q4-results",
            "pub_date": "2026-02-27 05:51:16",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a0c12024c37e0001bbc2d8",
            "title": "SoundHound AI Stock Flat After Q4 Earnings: Details",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>SoundHound AI Inc. </strong><a class=\"ticker-link\" data-exchange=\"NASDAQ\" data-ticker=\"SOUN\" href=\"https://www.benzinga.com/quote/SOUN\" rel=\"noopener\" target=\"_blank\">(NASDAQ:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/SOUN\" target=\"_blank\">SOUN</a>)<!-- --> shares were mostly flat in Thursday's extended trading after the company released its <a href=\"https://www.benzinga.com/quote/SOUN\" target=\"_blank\">fourth-quarter earnings report. </a></p><!--/$--><!--$--><p class=\"block core-block\">Here's a look at the details from the quarter. </p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>SOUN stock is moving. <a href=\"https://www.benzinga.com/quote/SOUN\" target=\"_blank\">Watch the price action here.</a></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><strong>The Details: </strong>SoundHound AI reported quarterly losses of two cents per share, in line with the consensus estimate.</p><!--/$--><!--$--><p class=\"block core-block\">Quarterly revenue came in at $55.06 million, which beat the Street estimate of $53.99 million and was up from $34.54 million in the same period last year.</p><!--/$--><!--$--><p class=\"block core-block\">SoundHound reported the following full-year highlights: </p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li>Full year reported revenue was $168.9 million, an increase of 99% year-over-year</li>\n<li>Full year non-GAAP gross margin was 58%</li>\n<li>Full year non-GAAP net loss was $53.9 million</li>\n<li>Full year adjusted EBITDA was a loss of $58.4 million</li>\n<li>Full year non-GAAP earnings per share were a loss of 13 cents</li>\n</ul><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><p class=\"block core-block\">“As traditional software faces massive AI disruption, businesses are looking to partner with AI natives that can help them achieve success in a new era. This is creating strong tailwinds for SoundHound,” said <strong>Keyvan Mohajer</strong>, CEO of SoundHound AI. </p><!--/$--><!--$--><p class=\"block core-block\">“Our results speak for themselves. All key profit metrics were up and in the last quarter we closed a record number of customer deals as we capitalized on the surge in demand for enterprise-grade AI,” Mohajer added. </p><!--/$--><!--$--><p class=\"block core-block\"><strong>SOUN Stock Price:</strong> According to data from<a href=\"https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw\" target=\"_blank\"> Benzinga Pro</a>, SoundHound stock rose 0.23% to $9 in Thursday's extended trading.  </p><!--/$--><!--$--><p class=\"block core-block\"><em>Photo: Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50914395\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/26/Porto--Portugal---October-25th--2024-Sou.jpeg",
            "link": "https://www.benzinga.com/markets/earnings/26/02/50914395/soundhound-ai-stock-flat-after-q4-earnings-details",
            "pub_date": "2026-02-27 05:54:44",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a0bef424c37e0001bbbf68",
            "title": "Here&#39;s How Much $100 Invested In Cigna Group 15 Years Ago Would Be Worth Today",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">Cigna Group (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/CI\" target=\"_blank\">CI</a>) has outperformed the market over the past 15 years by 1.77% on an annualized basis producing an average annual return of 13.4%. Currently, Cigna Group has a market capitalization of $77.07 billion. </p><!--/$--><!--$--><p class=\"block core-block\"><strong>Buying $100 In CI:</strong> If an investor had bought $100 of CI stock 15 years ago, it would be worth <strong>$659.11</strong> today based on a price of $288.53 for CI at the time of writing.</p><!--/$--><!--$--><h3 class=\"block core-block\">Cigna Group's Performance Over Last 15 Years</h3><!--/$--><!--$?--><template id=\"B:1\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p><!--/$--><!--$--><p class=\"block core-block\"><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--></div></div>",
            "image": "",
            "link": "https://www.benzinga.com/insights/news/26/02/50913706/heres-how-much-100-invested-in-cigna-group-15-years-ago-would-be-worth-today",
            "pub_date": "2026-02-27 05:45:28",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        }
    ]
}